UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2020

Portola Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35935

20-0216859

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

270 E. Grand Avenue

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 246-7300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock

PTLA

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 8.01 Other Events

On June 12, 2020, Portola Pharmaceuticals, Inc. (“Portola”) received written notice of termination from Bayer AG, successor to Bayer Pharma AG (“Bayer”) of a certain Clinical Collaboration Agreement, dated February 1, 2016, by and between Portola and Bayer (the “Agreement”). The Agreement permits termination by Bayer within 90 days of receiving written notice from Portola that its Third Party Collaboration Partner (as defined in the Agreement) has terminated the Third Party Agreement (as defined in the Agreement) with Portola for the development and commercialization of andexanet alfa in Japan as a reversal agent for Factor Xa inhibitors, including rivaroxaban.

Pursuant to the terms of the Agreement, the termination became effective on June 12, 2020 and the parties will work together to unwind the Agreement.

As disclosed by Portola on April 9, 2020, Portola informed Bayer that Portola had agreed to terminate its Collaboration and License Agreement with Bristol-Myers Squibb Company (“BMS”) and Pfizer, Inc. (“Pfizer”), and received written notice of termination from BMS and Pfizer on April 3, 2020. Following the BMS and Pfizer termination, Portola regains full rights in Japan for andexanet alfa. Currently, Japan represents the third largest market for Factor Xa inhibitors after the United States and the EU 5 countries. Portola will have exclusive rights to develop and commercialize andexanet alfa in the United States, Europe, Japan and rest of the world markets.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Portola Pharmaceuticals, Inc.

Dated: June 17, 2020

By:

/s/ Mike Ouimette

Mike Ouimette

Vice President and Assistant Corporate Secretary, Legal

PORTOLA PHARMACEUTICALS INC 8-K